

Franco Fais

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5575157/publications.pdf>

Version: 2024-02-01

81
papers

6,810
citations

172386

29
h-index

71651

76
g-index

86
all docs

86
docs citations

86
times ranked

5622
citing authors

#	ARTICLE	IF	CITATIONS
1	LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells. <i>Hematological Oncology</i> , 2022, 40, 41-48.	0.8	5
2	MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells. <i>Blood Advances</i> , 2022, 6, 5593-5612.	2.5	3
3	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	0.6	72
4	Validation of the Alternative International Prognostic Score (AIPSA): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-CISL protocol. <i>European Journal of Haematology</i> , 2021, 106, 831-835.	1.1	6
5	Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. <i>Frontiers in Oncology</i> , 2021, 11, 640731.	1.3	12
6	SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates migration in the MDA-MB-231 cell line. <i>BMC Molecular and Cell Biology</i> , 2021, 22, 41.	1.0	4
7	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621.	1.3	6
8	Establishment and Characterization of a Novel Fibroblastic Cell Line (SCI13D) Derived from the Broncho-Alveolar Lavage of a Patient with Fibrotic Hypersensitivity Pneumonitis. <i>Biomedicines</i> , 2021, 9, 1193.	1.4	3
9	Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. <i>Cells</i> , 2021, 10, 98.	1.8	23
10	Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNF α , IL-6 and IL-11 cytokines. <i>Haematologica</i> , 2021, 106, 2598-2612.	1.7	9
11	Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients. <i>Scientific Reports</i> , 2020, 10, 16519.	1.6	11
12	Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. <i>Frontiers in Oncology</i> , 2020, 10, 593383.	1.3	50
13	Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. <i>Scientific Reports</i> , 2020, 10, 18427.	1.6	13
14	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 869-880.	1.9	10
15	Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach. <i>Molecular Medicine</i> , 2020, 26, 25.	1.9	17
16	Frequency and clinical relevance of coding and noncoding <i>NOTCH1</i> mutations in early stage Binet A chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2020, 38, 406-408.	0.8	5
17	Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth. <i>International Journal of Molecular Sciences</i> , 2019, 20, 292.	1.8	10
18	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	13

#	ARTICLE	IF	CITATIONS
19	A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2018, 103, e531-e536.	1.7	24
20	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219.	2.0	15
21	Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. <i>Leukemia</i> , 2017, 31, 1894-1904.	3.3	33
22	Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway. <i>Scientific Reports</i> , 2017, 7, 14159.	1.6	14
23	A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI). <i>Clinical Immunology</i> , 2016, 172, 52-60.	1.4	4
24	Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt. <i>Scientific Reports</i> , 2016, 6, 25092.	1.6	67
25	Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. <i>Scientific Reports</i> , 2016, 6, 34449.	1.6	20
26	Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2015, 6, 22624-22640.	0.8	30
27	Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma. <i>Cancer Discovery</i> , 2014, 4, 110-129.	7.7	100
28	Dependence of Immunoglobulin Class Switch Recombination in B Cells on Vesicular Release of ATP and CD73 Ectonucleotidase Activity. <i>Cell Reports</i> , 2013, 3, 1824-1831.	2.9	72
29	IgS Expressed by Chronic Lymphocytic Leukemia B Cells Show Limited Binding-Site Structure Variability. <i>Journal of Immunology</i> , 2013, 190, 5771-5778.	0.4	21
30	Targeting the Bcl-2 family in B-cell chronic lymphocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 397-407.	0.7	1
31	Expression of Immunoglobulin Receptors with Distinctive Features Indicating Antigen Selection by Marginal Zone B Cells from Human Spleen. <i>Molecular Medicine</i> , 2013, 19, 294-302.	1.9	16
32	BH3-Only Proteins in Cancer and Apoptosis. , 2013, , 205-249.		0
33	N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity. <i>Leukemia</i> , 2012, 26, 2260-2268.	3.3	23
34	A Vector Design that Allows Fast and Convenient Production of Differently Tagged Proteins. <i>Molecular Biotechnology</i> , 2012, 52, 16-25.	1.3	1
35	A Soluble Form of CTLA-4 Is Present in Paediatric Patients with Acute Lymphoblastic Leukaemia and Correlates with CD1d+ Expression. <i>PLoS ONE</i> , 2012, 7, e44654.	1.1	40
36	Intraclonal Cell Expansion and Selection Driven by B Cell Receptor in Chronic Lymphocytic Leukemia. <i>Molecular Medicine</i> , 2011, 17, 834-839.	1.9	9

#	ARTICLE	IF	CITATIONS
37	Mutation Pattern of Paired Immunoglobulin Heavy and Light Variable Domains in Chronic Lymphocytic Leukemia B Cells. <i>Molecular Medicine</i> , 2011, 17, 1188-1195.	1.9	11
38	High frequency of development of B cell lymphoproliferation and diffuse large B cell lymphoma in Dbl knock-in mice. <i>Journal of Molecular Medicine</i> , 2011, 89, 493-504.	1.7	6
39	BH3-only proteins: The death-puppeteer's wires. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2010, 77A, 11-21.	1.1	37
40	The recruitment of two consecutive and different waves of host stem/progenitor cells during the development of tissue-engineered bone in a murine model. <i>Biomaterials</i> , 2010, 31, 2121-2129.	5.7	93
41	Role of the B-cell receptor in chronic lymphocytic leukemia: where do we stand?. <i>Italian Journal of Anatomy and Embryology</i> , 2010, 115, 79-84.	0.1	0
42	Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms. <i>Haematologica</i> , 2009, 94, 967-974.	1.7	19
43	Recruitment of a Host's Osteoprogenitor Cells Using Exogenous Mesenchymal Stem Cells Seeded on Porous Ceramic. <i>Tissue Engineering - Part A</i> , 2009, 15, 2203-2212.	1.6	83
44	Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. <i>Cancer Biology and Therapy</i> , 2009, 8, 263-271.	1.5	21
45	Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds. <i>Carcinogenesis</i> , 2009, 30, 150-157.	1.3	102
46	CX3CR1 Is Expressed by Human B Lymphocytes and Meditates CX3CL1 Driven Chemotaxis of Tonsil Centrocytes. <i>PLoS ONE</i> , 2009, 4, e8485.	1.1	40
47	Human Cytomegalovirus Regulates Surface Expression of the Viral Protein UL18 by Means of Two Motifs Present in the Cytoplasmic Tail. <i>Journal of Immunology</i> , 2008, 180, 969-979.	0.4	8
48	Assessment of RT-PCR Detection of Human Mammaglobin for the Diagnosis of Breast Cancer Derived Pleural Effusions. <i>Diagnostic Molecular Pathology</i> , 2008, 17, 28-33.	2.1	10
49	Similarities and Differences Between the Light and Heavy Chain Ig Variable Region Gene Repertoires in Chronic Lymphocytic Leukemia. <i>Molecular Medicine</i> , 2006, 12, 300-308.	1.9	20
50	Relationship between human mammaglobin mRNA expression in breast cancer tissue and clinico-pathologic features of the tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2006, 25, 65-72.	0.4	4
51	Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. <i>Blood</i> , 2005, 106, 3846-3853.	0.6	110
52	CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. <i>Leukemia</i> , 2005, 19, 551-556.	3.3	49
53	Inhibitory Receptors CD85j, LAIR-1, and CD152 Down-Regulate Immunoglobulin and Cytokine Production by Human B Lymphocytes. <i>Vaccine Journal</i> , 2005, 12, 705-712.	3.2	77
54	Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood. <i>Journal of Experimental and Clinical Cancer Research</i> , 2005, 24, 265-71.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia. <i>Journal of Experimental Medicine</i> , 2004, 200, 519-525.	4.2	370
56	IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2004, 133, 060118040555003.	1.2	20
57	CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates α -galactosylceramide presentation to natural killer T lymphocytes. <i>International Journal of Cancer</i> , 2004, 109, 402-411.	2.3	78
58	MULTIPLE SETS OF STEREOTYPED IMMUNOGLOBULIN VARIABLE REGIONS SUGGEST A ROLE FOR ANTIGEN IN THE EVOLUTION OF B-CLL.. <i>Journal of Investigative Medicine</i> , 2004, 52, S389.	0.7	0
59	Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2004, 113, 1008-1016.	3.9	190
60	The PML gene is not involved in the regulation of MHC class I expression in human cell lines. <i>Blood</i> , 2003, 101, 3514-3519.	0.6	28
61	B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. <i>Blood</i> , 2002, 99, 4087-4093.	0.6	294
62	Analysis of stepwise genetic changes in an AIDS-related Burkitt's lymphoma. <i>International Journal of Cancer</i> , 2000, 88, 744-750.	2.3	7
63	Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes. <i>Leukemia</i> , 2000, 14, 811-815.	3.3	45
64	Chronic lymphocytic leukemia: A proliferation of B cells at two distinct stages of differentiation.. <i>Current Topics in Microbiology and Immunology</i> , 2000, 252, 285-292.	0.7	9
65	Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999, 94, 1840-1847.	0.6	2,291
66	Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. <i>Leukemia</i> , 1999, 13, 1093-1099.	3.3	70
67	Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999, 94, 1840-1847.	0.6	46
68	Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. <i>Blood</i> , 1999, 94, 1840-7.	0.6	806
69	Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.. <i>Journal of Clinical Investigation</i> , 1998, 102, 1515-1525.	3.9	759
70	Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. <i>Blood</i> , 1996, 87, 1586-1594.	0.6	41
71	Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. <i>Blood</i> , 1996, 87, 3869-3876.	0.6	68
72	Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome. <i>Blood</i> , 1996, 88, 599-608.	0.6	20

#	ARTICLE	IF	CITATIONS
73	Lymphoblastoid cells transfected with c-myc: Downregulation of EBV-lytic antigens and impaired response of autologous CD4+ T cells in vitro. , 1996, 68, 810-816.		8
74	Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.. Journal of Clinical Investigation, 1996, 98, 1659-1666.	3.9	57
75	Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. Blood, 1996, 87, 1586-94.	0.6	12
76	Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Blood, 1996, 87, 3869-76.	0.6	22
77	Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.. Journal of Experimental Medicine, 1995, 181, 699-711.	4.2	55
78	Ig H and L Chain Variable Region Gene Sequence Analyses of Twelve Synovial Tissue-Derived B Cell Lines Producing IgA, IgG, and IgM Rheumatoid Factors Structure/Function Comparisons of Antigenic Specificity, V Gene Sequence, and IG Isotype. Autoimmunity, 1995, 22, 229-243.	1.2	7
79	Cellular Mechanisms of Artificial Peptides Binding to HLA. International Journal of Artificial Organs, 1991, 14, 518-522.	0.7	0
80	Cellular mechanisms of artificial peptides binding to HLA. International Journal of Artificial Organs, 1991, 14, 518-22.	0.7	0
81	Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements. Frontiers in Oncology, 0, 12, .	1.3	4